Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma

[1]  N. Hiraoka,et al.  Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma , 2011, British Journal of Cancer.

[2]  J. Silverman,et al.  Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma , 2009, Modern Pathology.

[3]  A. Marchetti,et al.  Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Y. Takeda,et al.  Molecular prediction of early recurrence after resection of hepatocellular carcinoma. , 2009, European journal of cancer.

[5]  Jia Fan,et al.  Role of overexpression of CD151 and/or c‐Met in predicting prognosis of hepatocellular carcinoma , 2009, Hepatology.

[6]  L. Trusolino,et al.  Drug development of MET inhibitors: targeting oncogene addiction and expedience , 2008, Nature Reviews Drug Discovery.

[7]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[8]  S. Thorgeirsson,et al.  Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. , 2006, The Journal of clinical investigation.

[9]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[10]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[11]  K. Furge,et al.  Met receptor tyrosine kinase: enhanced signaling through adapter proteins , 2000, Oncogene.

[12]  P. Comoglio,et al.  Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas , 2000, Oncogene.

[13]  S. Chevret,et al.  A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. , 1999, Journal of hepatology.

[14]  W. Linehan,et al.  Novel mutations of the MET proto-oncogene in papillary renal carcinomas , 1999, Oncogene.

[15]  L. Schmidt,et al.  Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. , 1999, Cancer research.

[16]  P Boffetta,et al.  A meta‐analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma , 1998, International journal of cancer.

[17]  S. Scherer,et al.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas , 1997, Nature Genetics.

[18]  J. Fujimoto,et al.  Expression of hepatocyte growth factor and its receptor c‐met proto‐oncogene in hepatocellular carcinoma , 1997, Hepatology.

[19]  B. Nordlinger,et al.  Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  J. Bruix,et al.  c‐met mRNA overexpression in human hepatocellular carcinoma , 1994, Hepatology.

[21]  H. Hasegawa,et al.  Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients , 1985, Cancer.

[22]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[23]  P. Jänne,et al.  MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  P. Scherle,et al.  Targeting the c-MET signaling pathway for cancer therapy. , 2008, Expert opinion on investigational drugs.

[25]  M. Sobrinho-Simões,et al.  The prognostic significance of amplification and overexpression of c‐met and c‐erb B‐2 in human gastric carcinomas , 2000, Cancer.